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Introduction: Pemetrexed is synergistic with gemcitabine in pre-
clinical models of non-small cell lung cancer (NSCLC). The optimal
dose and utility of gemcitabine and pemetrexed was evaluated in a
dose-escalating study.
Methods: The phase 1 study included patients with advanced
tumors, whereas the phase 2 study included patients with locally
advanced or metastatic NSCLC. Gemcitabine was infused over 30
minutes, followed by pemetrexed administered over 10 minutes on
day 1 of a 14-day cycle. Treatment continued for 12 cycles or until
disease progression. All patients received folic acid, Vitamin B12,
and steroid prophylaxis.
Results: Maximum tolerated dose was gemcitabine 1500 mg/m2,
followed by pemetrexed 500 mg/m2. Fifty-three patients (29 male,
24 female) were enrolled in the phase 2 study. Response rate was
20.8% (95% CI: 0.108–0.341), and the clinical benefit rate (CR 
PR  SD) was 64.2%. Median time to disease progression was 4.6
months (95% CI: 2.79–6.18), median survival was 10.1 month (95%
CI: 5.95–14.09, censorship 20.75%), and 1-year survival was 41.0%.
Common grade 3 or 4 adverse events (% of patients) were neutropenia
(28.3%), fatigue (22.6%), and febrile neutropenia (9.4%).
Conclusions: Twice-monthly gemcitabine and pemetrexed was well
tolerated, with overall survival and clinical benefit indicating disease
activity in NSCLC patients.
Key Words: Dose escalation, Gemcitabine, Non-small cell lung
cancer, Pemetrexed, Twice-monthly, Nonplatinum doublet.
(J Thorac Oncol. 2008;3: 394–399)
Up to 48% of patients with non-small cell lung cancer(NSCLC) are diagnosed with locally advanced stage III
or metastatic stage IV disease, making them ineligible for
curative surgery and likely to have a poor prognosis.1,2
Platinum-based doublets are associated with substantial he-
matologic toxicity, nephrotoxicity, nausea, and vomiting,
despite providing a survival benefit compared with single-
agent platinum or nonplatinum agents.3 Furthermore, no
survival differences have been observed between any of the
different platinum-based doublets4,5 or between platinum and
nonplatinum doublets.6,7
Preclinical studies evaluating pemetrexed and gemcit-
abine have reported synergy of the combination in non-small
cell lung carcinoma xenografts,8,9 as well as other tumor
types.8,9 Pemetrexed has shown comparable efficacy to do-
cetaxel with reduced toxicity as a single agent for the second-
line treatment of locally advanced or metastatic NSCLC.10
Supplementation with Vitamin B12 and folic acid has been
shown to reduce the toxicity of pemetrexed.11 Gemcitabine
has demonstrated independent antitumor activity in locally
advanced or metastatic NSCLC.12,13 Initial phase 2 studies in
NSCLC combining these two agents have employed a 90-
minute delay between administration.14,15 A pharmacokinetic
study,16 however, and subsequent phase 2 studies of the
combination17,18 have indicated that this delay in administra-
tion may be unnecessary. Most clinical studies employing
pemetrexed and gemcitabine in stage IIIB-IV NSCLC have
used a 21-day schedule.14,15,17,18 By comparison, dosing once
every 2 weeks theoretically offers the potential of increased
dose intensity and added patient convenience. The potential
benefit of this regimen is supported by the findings of a phase
2 study of docetaxel and gemcitabine, in which a twice-
monthly regimen resulted in a response rate of 55.7%.19
The current nonrandomized dose-escalating phase 1
and 2 study was designed to determine the optimal dose of
*University of Minnesota Comprehensive Cancer Center, Minneapolis, Min-
nesota; †Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota;
‡Florida Cancer Specialists, Fort Myers, Florida; §Minnesota CGOP,
Minneapolis, Minnesota; Dallas VA Medical Center, Dallas, Texas;
¶Marshfield Clinic Research Foundation, Wisconsin; #University of
Rochester, Rochester, New York; **Eli Lilly and Company, Indianapo-
lis, Indiana.
Disclosure: Arkadiusz Z. Dudek, Speaker’s bureau for Eli Lilly and Com-
pany. Jane L. Bromund, Ruqin Chen, Matthew J. Monberg, and Coleman
K. Obasaju are employees of Eli Lilly and Company.
Address for correspondence: Arkadiusz Z. Dudek, MD, PhD, University of
Minnesota, MMC 480, 420 Delaware St SE, Minneapolis, MN 55455.
E-mail: dudek002@umn.edu
This trial was sponsored by Eli Lilly and Company and was previously
presented at the 2007 World Conference on Lung Cancer and the 2004
and 2006 American Society of Clinical Oncology meetings.
Copyright © 2008 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/08/0304-0394
Journal of Thoracic Oncology • Volume 3, Number 4, April 2008394
twice-monthly gemcitabine followed by pemetrexed, as well
as evaluate the efficacy and safety of this regimen when
administered without a 90-minute delay. A phase 1 adden-
dum was also conducted to evaluate the reverse sequence of
biweekly pemetrexed 500 mg/m2, followed by gemcitabine
1500 mg/m2.
METHODS
Patients were enrolled in three types of research proto-
cols (phase 1, phase 2, and phase 1 addendum) from seven
institutions in the United States between April 2003 and
September 2005. Protocols were approved by each institu-
tion’s committee on human experimentation. The trial has
been registered with a public database (www.clinicaltrials-
.gov).
Patient Selection
Phase 1 and Phase 1 Addendum
Phase 1 protocols were open to patients with solid-
tumor cancer that was not curable by standard treatments.
Eligible patients were at least 18-year-old and had an Eastern
Cooperative Oncology Group performance status of 0 or 1, a
life expectancy 12 weeks, and adequate organ function and
bone marrow reserve (defined as absolute neutrophil count
2.0 109/L; platelet count100 109/L; hemoglobin9
g/dl; bilirubin 1.5 times institutional upper limit of normal
[ULN]; alkaline phosphatase, aspartate transaminase, and
alanine transaminase 3 times institutional ULN; and calcu-
lated creatinine clearance45 ml/min using the Cockroft and
Gault formula).20 Patients were eligible if they had received
only one prior chemotherapy treatment or. prior radiation
therapy to25% of the bone marrow if completed2 weeks
before enrollment.
Phase 2
The phase 2 protocol used the same eligibility criteria
as above, with the exception of the following additional
restrictions. Eligible patients had histologically or cytologi-
cally confirmed locally advanced or metastatic NSCLC (stage
IIIb with pleural effusion or stage IV), measurable by
RECIST criteria21 and not surgically resectable. Prior radia-
tion therapy to 25% of the bone marrow was allowed if
completed 4 weeks before enrollment (whole pelvis irradi-
ation was not allowed). Patients who had received prior
chemotherapy, immunotherapy, or biologic therapy for
NSCLC were excluded.
Drug Schedule
Drug products were supplied by Eli Lilly and Company
(Indianapolis, IN). Phase 1 and 2 treatment protocols con-
sisted of gemcitabine administered over 30 minutes, followed
immediately by pemetrexed delivered over 10 minutes on day
1 of a 14-day cycle. The drug sequence for the phase 1
addendum protocol was reversed, with pemetrexed given
initially followed immediately by gemcitabine. All treatment
protocols were continued for 12 cycles or until progressive
disease.
Dose-Escalation Scheme
The initial dose was gemcitabine 1250 mg/m2 followed
by pemetrexed 500 mg/m2. Three patients entered the initial
dose level. Doses were incremented until the maximum tolerated
dose (MTD) was reached. MTD was defined as the dose causing
more than one third of patients to have a dose-limiting toxicity
(DLT) following the first treatment cycle. Toxicities were graded
using the Common Toxicity Criteria [CTC Version 2.0].22
Statistical Considerations (Phase 2 Only)
This open-label, phase 2 trial was conducted in two
stages.23 Up to 48 qualified patients were enrolled with the
possibility of stopping the study early for either lack of
efficacy or unacceptable toxicity. During the first stage, 18
qualified patients were enrolled. If greater than three patients
responded, accrual continued until a minimum of 48 patients
were included. If responses are seen in 12 or fewer patients,
this regimen will be deemed not worthy of any further
investigation in this patient population, unless clinical con-
siderations suggest otherwise. The probability of stopping
early after stage one was 48.0% if the true response rate
was 15% (H0), and 2.4% if the true response rate was
35% (Ha). The overall probabilities of type I and type II
errors were 0.021 and 0.105, respectively.
The primary objective was the demonstration of an
improvement in response rates. The study was also designed
to evaluate time to disease progression (TTP), overall sur-
vival, and toxicity in this population. The Kaplan-Meier
method was used to estimate TTP and overall survival.24
RESULTS
Phase 1
A total of 40 patients were enrolled into the phase 1
portion of the study. Primary tumor types included lung
(37.5%), mesothelioma (12.5%), head and neck (10%), pan-
creas (10.0%), and esophagus cancers (7.5%). The median
age was 57.5 years, and 62.5% were male. The MTD was
determined to be gemcitabine 1500 mg/m2, followed by
pemetrexed 500 mg/m2. DLTs at this level were grade 3
diarrhea, hypotension, and atrial fibrillation. An unconfirmed
CR or PR was observed in five patients at the MTD. DLTs
and unconfirmed responses for all dose levels are summarized
in Table 1.
Phase 2
Patient Characteristics
A total of 53 patients enrolled in the phase 2 portion of
the study. Baseline patient characteristics are summarized in
Table 2. Median age was 64.0 years, 81.1% has stage IV
disease, and 60.4% had an Eastern Cooperative Oncology
Group performance status of 1. For all treated patients, the
median number of cycles administered was 5.0. Patient drug
exposure is summarized in Table 3. Twenty-three (43.4%)
patients had one or more dose adjustments, with 14 (26.4%)
patients requiring dose reduction, 5 (9.4%) of whom required
two or more reductions. Dose delays occurred in 15 (28.3%)
patients and were most commonly due to a grade 3 or 4
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adverse event. Median dose intensity (actual dose/planned
dose) was 98.1% for both gemcitabine and pemetrexed.
Antitumor Activity
Tumor response rates are shown in Table 4. Confirmed
partial responses were recorded in 11 (20.8%) of the 53 of
patients in the intent-to-treat population (95% CI: 0.108–
0.341). Stable disease was reported for 23 patients (43.4%);
PD was reported for 14 patients (26.4%); response was
unknown/unavailable for 5 (9.4%) patients. The median du-
ration of response was 10.3 months (95% CI: 3.22–20.04),
and the clinical benefit rate (CR  PR  SD) was 64.2%.
Sustained duration of response was 63.6% at 6 months and
45.5% at 12 months. Median TTP was 4.6 months (see Figure
1A; 95% CI: 2.79–6.18, censorship  37.7%). Median sur-
TABLE 1. Phase 1 Results
Dose Level G P N Cycle 1 DLTs Types of DLTsab Responses
1 1250 500 3 1 Grade 4 neutropenia 1
2 1500 500 9 2 Grade 3 diarrhea; grade 3 hypotension, grade 3 atrial fibrillation 5
3 1750 500 10 2 Grade 3 shortness of breath; grade 3 anxiety, grade 3 insomnia 2
4 2000 500 6 4 Grade 3 fatigue, grade 4 thrombocytopenia; grade 3 maculopapular rash;
grade 4 hepatitis acute, grade 4 respiratory failure, grade 4 atrial fibrillation,
grade 4 renal insufficiency, grade 4 hypotension, grade 4 depressed level of
consciousness; grade 3 anemia, grade 3 lower abdominal pain, grade 3
necrotic renal mass
0
5 1500 600 6 4 Grade 4 pulmonary embolism, grade 3 hypoxia; grade 3 shortness of breath,
grade 3 diarrhea, grade 3 febrile neutropenia (2); grade 4 weakness of
limbs, grade 3 dehydration; grade 3 abdominal pain, grade 4 small bowel
obstruction, grade 4 constipation, grade 3 pancreatitis, grade 3 lipase
increased, grade 3 hemoglobin (anemia)
1
DLT, dose limiting toxicity; G, gemcitabine; N, number of patients assigned to each dose level; P, pemetrexed.
a Individual patients may have experienced more than one type of DLT within a dose level. Individual patients are separated in this column by a semicolon.
b DLT was defined as grade 4 neutropenia lasting5 d, grade 4 febrile neutropenia, grade 4 thrombocytopenia, or grade3 nonhematologic toxicity (excluding alopecia, nausea,
or vomiting, and transaminase elevations).
TABLE 2. Baseline Characteristics: Phase 2 Study Only
Variable N  53
Age
Median, yr (range) 64.4 (35–80)
65 yr 29 (54.7%)
Gender
Male 29 (54.7%)
Female 24 (45.3%)
ECOG performance status
0 20 (37.7%)
1 32 (60.4%)
Not available 1 (1.9%)
Pathologic diagnosis
Histopathologic 35 (66.0%)
Cytologic 18 (34.0%)
Stage of disease
Stage IIIB 10 (18.9%)
Stage IV 43 (81.1%)
Prior radiation therapy
None 41 (77.4%)
1 9 (17.0%)
2 2 (3.8%)
3 1 (1.9%)
Prior surgical procedures
None 32 (60.4%)
1 17 (32.1%)
2 3 (5.7%)
3 1 (1.9%)
ECOG, Eastern Cooperative Oncology Group; N, number of patients within phase
2 intent-to-treat population.
TABLE 3. Summary of Dose Administration for the Phase 2
Study
Dosing Variable N  53
No. cycles
Sum (range) 309 (1–12)
Mean 5.8
Median 5.0
No. patients with dose adjustments 23 (43.4%)
No. with delays 15 (28.3%)
No. with omissions 1 (1.9%)
No. with reductions 14 (26.4%)
No. patients with
1 dose reduction 9 (64.3%)
2 dose reductions 5 (35.7%)
3 dose reductions 0
No. dose reductions
Sum 19 (6.1%)
Mean 1.4
Median 1.0
Relative dose intensity for pemetrexed
Mean 92.0%
Median 98.1%
Range 58.9–107.5%
Relative dose intensity for gemcitabine
Mean 92.4%
Median 98.1%
Range 66.6–118.2%
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vival was 10.1 month (95% CI: 5.95–14.09, censorship 
20.8%) with survival rates of 41.0% at 1 year and 17.2% at 2
years.
Drug Safety
Grade 3 or 4 hematologic and nonhematologic toxici-
ties are summarized in Table 5. The most common grade 3 or
4 hematologic events (% of patients) were neutropenia
(28.3%), febrile neutropenia (9.4%), and thrombocytopenia
(5.7%). The most common grade 3 or 4 nonhematologic
events were fatigue (22.6%), cellulitis (7.5%), dehydration
(7.5%), and dyspnea (7.5%). Three patients developed seri-
ous adverse events related to dizziness. Of these, two discon-
tinued treatment due to severe (grade 3) abnormal coordina-
tion and grade 2 vertigo, whereas one developed a balance
disorder but completed the study. Overall, 15 (28.3%) pa-
tients received one or more blood transfusions. All 15
(28.3%) patients received packed red blood cells; platelets
were received by one patient (1.9%).
Phase 1 Addendum
Of 13 patients enrolled in the phase 1 addendum, 8
received the correct drug sequence of pemetrexed and gem-
citabine (evaluable patients) and 5 received the incorrect drug
sequence of gemcitabine and pemetrexed (nonevaluable pa-
tients). Two patients each in the evaluable and nonevaluable
groups had unconfirmed PRs. DLTs were observed for 3 of 8
evaluable patients and 1 of 5 nonevaluable patients at a
pemetrexed and gemcitabine dose of 500/1500 mg/m2. Ad-
ministration of the reverse sequence was discontinued early
per the stopping rules when three DLTs were observed.
FIGURE 1. A, B, Time to disease progression and survival
for the phase 2 study. CI, confidence intervals; ITT, intent-
to-treat; TTP, time to disease progression.
TABLE 4. Tumor Response: Phase 2 Study
Response Variable N  53
Complete response, n (%) 0 (0.0%)
95% CI NE–NE
Partial response, n (%) 11 (20.8%)
95% CI 0.108–0.341
Stable disease, n (%) 23 (43.4%)
95% CI 0.298–0.577
Progressive disease, n (%) 14 (26.4%)
95% CI 0.153–0.403
Unknown/unavailable, n (%) 5 (9.4%)
Median duration of response, mo 10.3
95% CI 3.22–20.04
Clinical benefit ratea, n (%) 34 (64.2%)
a Clinical benefit was defined as the number of patients with complete response,
partial response, or stable disease.
TABLE 5. Summary of Hematologic and Nonhematologic
Toxicities in Phase 2 Study
Patient-Based (N  53)
Cycle-Based
(N  312)
Grade 3
N (% pts)
Grade 4
N (% pts)
Grade 3/4
(% pts)
Grade 3/4
N (% cycles)
Hematologic
Neutropenia 7 (13.2) 8 (15.1) 28.3 21 (6.7)
Febrile neutropenia 4 (7.5) 1 (1.9) 9.4 5 (1.6)
Thrombocytopenia 3 (5.7) 0 (0.0) 5.7 3 (1.0)
Anemia 2 (3.8) 0 (0.0) 3.8 3 (1.0)
Nonhematologic
Fatigue 11 (20.8) 1 (1.9) 22.6 14 (4.5)
Cellulitis 3 (5.7) 1 (1.9) 7.5 5 (1.6)
Dyspnea 3 (5.7) 1 (1.9) 7.5 5 (1.6)
Dehydration 4 (7.5) 0 (0.0) 7.5 4 (1.3)
Alopecia (grade 1 or 2) 3 (5.7) –– –– 4 (1.3)
Diarrhea 3 (5.7) 0 (0.0) 5.7 3 (1.0)
Constipation 2 (3.8) 0 (0.0) 3.8 2 (0.6)
Hyponatremia 2 (3.8) 0 (0.0) 3.8 2 (0.6)
Nausea 2 (3.8) 0 (0.0) 3.8 2 (0.6)
Pneumonia 1 (1.9) 0 (0.0) 1.9 1 (0.3)
Rash 1 (1.9) 0 (0.0) 1.9 1 (0.3)
Vomiting 1 (1.9) 0 (0.0) 1.9 1 (0.3)
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CONCLUSIONS
This study has demonstrated the safety of combining
gemcitabine and pemetrexed as a first-line treatment for
locally advanced or metastatic NSCLC when gemcitabine is
administered followed without delay by pemetrexed on day 1
of a 14-day cycle. The phase 1 portion of this study has
established the MTD of gemcitabine as 1500 mg/m2 and
pemetrexed as 500 mg/m2. This MTD level is comparable to
the dose used for 21-day cycles, in which gemcitabine was
administered at 1250 mg/m2 on days 1 and 8 and pemetrexed
was given at 500 mg/m2 on either day 1 or 8.14,15,17,18 In the
present study, the MTD dose was well tolerated in the phase
2 study, with neutropenia (28.3%) as the most common
toxicity. Furthermore, the dose intensity exceeded previous
studies employing 21-day cycles of gemcitabine and pem-
etrexed in locally advanced or metastatic NSCLC (77.3% for
gemcitabine and 87.2% for pemetrexed).15
The combination of gemcitabine and pemetrexed is
active, with a response rate in our phase 2 study of 20.8% and
a median survival of 10.1 month. Two previous studies of
21-day gemcitabine and pemetrexed in first-line NSCLC with
a 90-minute delay between treatments were conducted by
Monnerat et al. and Ma et al.14,15 The Monnerat et al. study
produced a response rate of 15.5% and a median survival of
10.1 month, but a grade 3 or 4 neutropenia rate of 61.7% and
a grade 3 or 4 febrile neutropenia rate of 16.7%. Ma et al.
randomized patients to one of three 21-day schedules of
gemcitabine and pemetrexed. The preferred schedule in that
study was pemetrexed followed by gemcitabine on day 1 and
gemcitabine alone on day 8, which resulted in a slightly
higher grade 3 or 4 neutropenia rate of 64.4%, a response rate
of 31%, and a median survival of 11.4 months. Compared
with studies using a 90-minute delay between treatments on
a 21-day cycle, the current study seems to offer greater
tolerability and convenience with comparable response rates
and median survival times.
Two previous trials of 21-day gemcitabine and pem-
etrexed in first-line NSCLC without a 90-minute delay be-
tween treatments were conducted by West et al. (which
administered gemcitabine on days 1 and 8 and pemetrexed on
day 8)18 and Treat et al. (which administered gemcitabine on
days 1 and 8 and pemetrexed on day 1).17 In these two trials,
the median dose intensities were 82.2% and 76.8% for gem-
citabine and 83.2% and 93.9% for pemetrexed. These rates
are lower than the 98.1% and 98.1% median dose intensities
observed in the present trial. Furthermore, although median
survival rates were similar in all three trials (10 months),
grade 3 or 4 neutropenia was lower in the current trial
(28.3%) compared with the trials of West et al. (39.6%) and
Treat et al. (43.4%).
The clinical benefit of gemcitabine and pemetrexed in
first-line NSCLC were evaluated in a meta-analysis of data
from four previous phase 2 trials consisting of 220 total
patients.25 This analysis reported a median TTP of 4.17
months (95% CI: 3.29–5.06) and an overall survival of 10.25
months (95% CI: 8.74–11.17), both of which are similar to
the median times reported in the present study.
The primary rationale for the use of nonplatinum dou-
blets in NSCLC is the potential reduction of toxicity when
compared with the toxicity associated with platinum-based
doublets. In a three-arm phase 3 Coalition of National Cancer
Cooperative Groups trial, combination gemcitabine and pac-
litaxel were associated with similar efficacy, but reduced
hematologic toxicity, when compared with platinum-based
doublets.7 Nonplatinum doublets may also be an option for
patients who may be resistant to platinum therapy as indi-
cated by genotypic expression.26,27 Pemetrexed and gemcit-
abine administered as outlined in the present study met the
protocol-defined efficacy criteria, has favorable toxicity pro-
file, and should be further evaluated as a feasible alternative
to platinum-based doublets.
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